TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05931198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified illusion of the rubber (syncrhone)
Description: The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis at the same time (synchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
Study: NCT05806983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology Based Psychosocial Program
Description: A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
Study: NCT05782231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetActive+
Description: This is a 10-week group mind body program focused on improving self- report, performance based and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increased in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
Study: NCT05931198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified illusion of the rubber (asynchrone)
Description: The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis not at the same time (asynchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
Study: NCT05743881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1365
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1365
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1365
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) solution for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nimenrix
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nimenrix
Description: Solution for injection
Study: NCT05541497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate
Description: Days 1-3: 0.5mg study pill once per day, Days 4-7: 0.5mg study pill twice per day, Weeks 2-8: 1mg study pill twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day
Study: NCT05483907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-877
Description: BBT-877 24 weeks + Follow-up 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 24 weeks + Follow-up 4 weeks
Study: NCT06138587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine Induced Memory-like Natural Killer Cells
Description: Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.
Study: NCT05049031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: A questionnaire will be given to patients who will ask them about their possible fractures, their bone and oncological follow-ups and their possible cardiovascular events since the end of treatment with hormone therapy.
Study: NCT05504824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case-based education
Description: The education phase This stage included the explanation of the CR process, the analysis of CR cases, the drafting of new cases suitable for the CR process by students, and the analysis process.~The education program was carried out on a web platform (Zoom) consistent with the changes in the COVID-19 pandemic process. The CR cases to be used in case-based education were sent to the students via e-mail before the group interview to make sure students came prepared for the group discussion. In case-based education, after the students read the case, they were asked some questions to determine their decisions and reasoning.
Study: NCT06396637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride
Description: Sapropterin Dihydrochloride: 20mg/kg, qd
Study: NCT04950686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Aware for Young Adults
Description: Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults that uses a media literacy education (MLE) approach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Aware for Young Adults
Description: Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults.
Study: NCT05517174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine
Description: For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
Study: NCT06435312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Zilucoplan will be administered subcutaneously to pediatric study participants
Study: NCT06127901

Intervention type: PROCEDURE
Intervention: Any surgery under any type of anaesthesia.
Description: Any surgery under any type of anaesthesia.
Study: NCT04604782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR
Study: NCT05058352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS269
Description: Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.
Study: NCT04604782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR
Study: NCT05517174

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Dose Quadrivalent Influenza Vaccine
Description: Any standard-dose quadrivalent influenza vaccine administered in the Danish governmental influenza vaccine program may be used.
Study: NCT04940208

Intervention type: OTHER
Intervention: Pain and neuropsychological questionnaires
Description: Patient-reported outcomes, listed in the Secondary Outcome Measure Section

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory testing
Description: Summation pain threshold test and Heat pain threshold skin test
Study: NCT06191523

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group will receive standard therapy and placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group will receive standard therapy and placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Group
Description: The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Group
Description: The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
Study: NCT06028841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1553
Description: Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
Study: NCT06507969

Intervention type: OTHER
Intervention: The Effect of Body Composition on Respiratory Parameters, Functional Capacity and Sleep in Healthy Young Adults
Description: Sociodemographic information of all participants will be obtained within the scope of the evaluations. Body composition parameters will be measured with Tanita DC360 Body Analysis Scale. In pulmonary function test, Forced vital capacity (FVC), Forced expiratory volume in 1st second (FEV1), Tiffeneau ratio (FEV1/FVC), peak expiratory flow rate (PEF) values will be evaluated with COSMED Pony FX (COSMED; Italy) spirometer. Respiratory muscle endurance will be assessed by Maximum Minute Ventilation will be determined. Pittsburg Sleep Quality, a reliable questionnaire that assesses sleep quality The index will be filled in by the participants. 6 Minutes to assess functional capacity A walking test will be performed and the distance travelled by individuals will be recorded
Study: NCT05120596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab+T3P-Y058-739
Description: intravenous infusion or intratumoural injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3P-Y058-739 (IV)
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3P-Y058-739 (IT)
Description: Intratumoral use
Study: NCT05202379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: CC-42344 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: CC-42344 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: CC-42344 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: CC-42344 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: CC-42344 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: CC-42344 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: CC-42344 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: CC-42344 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: CC-42344 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules
Study: NCT06212921

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sequential blood samples
Description: Sequential blood samples for diagnostic tests is the only intervention in thei study
Study: NCT05650411

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMCA PCI with Biofreedom Ultra drug-coated stent (Biosensors International, Switzerland)
Description: Successful LMCA PCI with ≥1 BioFreedom Ultra polymer-free drug-coated stent (Biosensors International, Switzerland).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMCA PCI with Biofreedom Ultra drug-coated stent (Biosensors International, Switzerland)
Description: Successful LMCA PCI with ≥1 BioFreedom Ultra polymer-free drug-coated stent (Biosensors International, Switzerland).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor-based SAPT after short DAPT
Description: Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional DAPT
Description: 6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.
Study: NCT06253052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional pre-OP-visit
Description: OP-schedule is closely monitored and patients will be visited to support and encourage them in drinking clear fluids.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional pre-OP-visit
Description: OP-schedule is closely monitored and patients will be visited to support and encourage them in drinking clear fluids.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liberal fasting regime
Description: Patients may drink up to 200 ml clear fluids between 2 h prior to the surgery and the call to operation room.
Study: NCT06189716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow oxygen through nasal cannula
Description: High flow oxygen through nasal cannula and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions.
Study: NCT05300555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
Study: NCT05116007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
Study: NCT05285644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR 15512 Ophthalmic Solution
Description: Topical ocular administration of one drop in both eyes BID for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Study: NCT05304208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesopher
Description: autologous monocyte-derived DCs loaded with PheraLys (tumor cell lysate)
Study: NCT04407611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online modality
Description: Return of BRCA results directly online or return of printed BRCA results if participant cannot access online or chooses not to

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic counselor follow-up
Description: Optional genetic counselor follow-up over the telephone
Study: NCT06680999

Intervention type: OTHER
Intervention: Data collection
Description: Preoperative, intraoperative and follow-up data collection: consultation and anesthesia reports, hospitalization reports and imaging data to evaluate the feasibility and efficacy of endovascular treatment of superior vena cava syndromes involving the trifurcation. Data collection will last 1 month and will be performed by a Vascular Surgery resident of the hospital.
Study: NCT06680115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine
Study: NCT06623149

Intervention type: BEHAVIORAL
Intervention: Non-Surgical Intervention
Description: After referral from the general practitioner to the orthopedic department, the patient is offered a 3-month non-operative treatment program. The conservative program consists of several elements that are offered on an individual basis. The program consists of 3 main elements:~* Patient education/information~* Specialized exercise supervised by a physiotherapist~* Weight loss counseling with a dietician

Intervention type: PROCEDURE
Intervention: Current practice
Description: After referral from the general practitioner to the orthopedic department, the patient is assessed by an orthopedic surgeon in the out-patient clinic according to standard practice with a focus on symptoms, history, physical examination, radiography, and an appraisal of the patient's expectations. If an indication for knee arthroplasty is found, the patient is offered knee arthroplasty, and if the patient accepts the offer, he/she is scheduled according to usual practice. If a patient declines the offer, the patient is informed that the hospital cannot offer any additional service, and the patient is referred back to primary care.
Study: NCT06681246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Description: 10 days of either antibiotics- Augmentin (amoxicillin+clauvonate), 875mg, 2 /day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consist of a combination of agarose in normal saline/glycerol
Study: NCT06681337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CART + CD19 CART
Description: BCMA CART + CD19 CART
Study: NCT06708624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYB201 0.5 mg (0.05 mL of 10 mg/mL)
Description: IVT administration of FYB201 in a PFS
Study: NCT06707662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker and defibrillator
Description: Pacemaker implantation, which can be a regular right ventricle apical lead or a LBBAP lead (LBBP or LVSP dependint on the criteria accomplished).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker and defibrillator
Description: Pacemaker implantation, which can be a regular right ventricle apical lead or a LBBAP lead (LBBP or LVSP dependint on the criteria accomplished).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker and defibrillator
Description: Pacemaker implantation, which can be a regular right ventricle apical lead or a LBBAP lead (LBBP or LVSP dependint on the criteria accomplished).
Study: NCT06707571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: spinal anesthesia after us-assisted technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: spinal anesthesia using the surface landmark-guided
Study: NCT06709664

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire study
Study: NCT06704347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: XT-150 is a small piece of plasmid DNA (genetic material) that produces a variant of the anti-inflammatory cytokine, Interleukin 10 (IL-10).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: XT-150 is a small piece of plasmid DNA (genetic material) that produces a variant of the anti-inflammatory cytokine, Interleukin 10 (IL-10).
Study: NCT06708104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outdoor horse-assisted perturbation training
Description: This is balance training in which a special carriage, i.e. a dynamic standing platform, is pulled by a horse on the outside surface, providing the trainee with multi-directional 3D balance perturbations that depend on the topography of the training area (various slopes and surface types), the horse walking speed, and its ability to stop, accelerate, and turns.
Study: NCT06710665

Intervention type: DRUG
Intervention: Chemotherapy
Description: Chemotherapy

Intervention type: DRUG
Intervention: Chemotherapy
Description: Chemotherapy
Study: NCT06080711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI assistance
Description: Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI assistance
Description: Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
Study: NCT05472870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
Study: NCT04953026

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnositic test
Description: The results of shoulder arthroscopy were taken as the gold standard, and MRI examination was taken as the research object.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnositic test
Description: The results of shoulder arthroscopy were taken as the gold standard, and MRI examination was taken as the research object.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnositic test
Description: The results of shoulder arthroscopy were taken as the gold standard, and MRI examination was taken as the research object.